{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004231521215104.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12185-018-2509-0"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/article/10.1007/s12185-018-2509-0/fulltext.html"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1007/s12185-018-2509-0.pdf"}},{"identifier":{"@type":"PMID","@value":"30032392"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2019223397"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma"}],"description":[{"notation":[{"@value":"Adult T-cell leukemia-lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6 months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004231521214991","@type":"Researcher","foaf:name":[{"@value":"Jun Nakashima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521215106","@type":"Researcher","foaf:name":[{"@value":"Yoshitaka Imaizumi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214995","@type":"Researcher","foaf:name":[{"@value":"Hiroaki Taniguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214989","@type":"Researcher","foaf:name":[{"@value":"Koji Ando"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214988","@type":"Researcher","foaf:name":[{"@value":"Masako Iwanaga"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326224077952","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70530442"},{"@type":"NRID","@value":"1000070530442"},{"@type":"NRID","@value":"9000308730985"},{"@type":"NRID","@value":"9000258044970"},{"@type":"NRID","@value":"9000412651502"},{"@type":"NRID","@value":"9000399524094"},{"@type":"NRID","@value":"9000403424671"},{"@type":"NRID","@value":"9000414079341"},{"@type":"NRID","@value":"9000019093268"},{"@type":"NRID","@value":"9000016397871"},{"@type":"NRID","@value":"9000398799242"},{"@type":"NRID","@value":"9000411811541"},{"@type":"NRID","@value":"9000411806773"},{"@type":"NRID","@value":"9000411816241"},{"@type":"NRID","@value":"9000396109151"},{"@type":"NRID","@value":"9000411816253"},{"@type":"NRID","@value":"9000403514786"},{"@type":"NRID","@value":"9000398139671"},{"@type":"NRID","@value":"9000258046113"},{"@type":"NRID","@value":"9000411818636"},{"@type":"NRID","@value":"9000360588241"},{"@type":"NRID","@value":"9000259332370"},{"@type":"NRID","@value":"9000411809262"},{"@type":"NRID","@value":"9000411817316"},{"@type":"NRID","@value":"9000411803260"},{"@type":"NRID","@value":"9000411816782"},{"@type":"NRID","@value":"9000313615135"},{"@type":"NRID","@value":"9000408791614"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/itonaga-h"}],"foaf:name":[{"@value":"Hidehiro Itonaga"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214978","@type":"Researcher","foaf:name":[{"@value":"Shinya Sato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214980","@type":"Researcher","foaf:name":[{"@value":"Yasuhi Sawayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214990","@type":"Researcher","foaf:name":[{"@value":"Tomoko Hata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214979","@type":"Researcher","foaf:name":[{"@value":"Shinichiro Yoshida"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521215105","@type":"Researcher","foaf:name":[{"@value":"Yukiyoshi Moriuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231521214996","@type":"Researcher","foaf:name":[{"@value":"Yasushi Miyazaki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09255710"},{"@type":"EISSN","@value":"18653774"}],"prism:publicationName":[{"@value":"International Journal of Hematology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2018-07-21","prism:volume":"108","prism:number":"5","prism:startingPage":"516","prism:endingPage":"523"},"reviewed":"false","dc:rights":["https://www.springer.com/tdm","https://www.springer.com/tdm"],"url":[{"@id":"https://link.springer.com/article/10.1007/s12185-018-2509-0/fulltext.html"},{"@id":"https://link.springer.com/content/pdf/10.1007/s12185-018-2509-0.pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2019223397"}],"createdAt":"2018-07-21","modifiedAt":"2022-07-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Aged,%2080%20and%20over","dc:title":"Aged, 80 and over"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal,%20Humanized","dc:title":"Antibodies, Monoclonal, Humanized"},{"@id":"https://cir.nii.ac.jp/all?q=Disease-Free%20Survival","dc:title":"Disease-Free Survival"},{"@id":"https://cir.nii.ac.jp/all?q=Survival%20Rate","dc:title":"Survival Rate"},{"@id":"https://cir.nii.ac.jp/all?q=Risk%20Factors","dc:title":"Risk Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Leukemia-Lymphoma,%20Adult%20T-Cell","dc:title":"Leukemia-Lymphoma, Adult T-Cell"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040282256949837824","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17K16189"},{"@type":"JGN","@value":"JP17K16189"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K16189/"}],"notation":[{"@language":"ja","@value":"DNAメチル化酵素の視点から治療関連白血病のマイクロRNAの制御破綻を俯瞰する"},{"@language":"en","@value":"Aberrant expression of mRNA regulated by DNA methyltransferases in therapy-related leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1040282256981337600","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18K16121"},{"@type":"JGN","@value":"JP18K16121"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K16121/"}],"notation":[{"@language":"ja","@value":"急性骨髄性白血病におけるDUSP4の役割と治療応用"},{"@language":"en","@value":"Role of DUSP4 in AML and  development of Novel  Therapy"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050016449465912448","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice"},{"@value":"Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235482844928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236881929600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144614710144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283694003942784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711855535488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620732285312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185443020928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and <scp>II</scp> studies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571472290176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869854339607808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361412891020972544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945221170688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T‐cell leukaemia‐lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420740712320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1–transformed T cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843575870080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793934299648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500693305088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801"},{"@value":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma."},{"@value":"Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12185-018-2509-0"},{"@type":"KAKEN","@value":"PRODUCT-22173830"},{"@type":"KAKEN","@value":"PRODUCT-22156270"},{"@type":"OPENAIRE","@value":"doi_dedup___::ecaefa620af62436af8ebd9f397b730c"},{"@type":"CROSSREF","@value":"10.1007/s12185-024-03857-2_references_DOI_RGKvGTKbqKxSeiktp5Qo7giDyKl"},{"@type":"CROSSREF","@value":"10.1007/s12185-019-02728-5_references_DOI_RGKvGTKbqKxSeiktp5Qo7giDyKl"}]}